Brief: Carmat Completes Enrolment In Eficas Study, Approved For 21 More Aeson Implants
12/05/2025 17:10
May 12 (Reuters) - Carmat SA ALCAR.PA: COMPLETES ENROLMENT IN THE EFICAS CLINICAL STUDY AND RECEIVES APPROVAL FROM FRENCH AUTHORITIES FOR 21 ADDITIONAL AESON® IMPLANTS, WHILE AWAITING POTENTIAL REIMBURSEMENT OF THE DEVICE IN FRANCE COMPLETES ENROLMENT IN EFICAS STUDY, APPROVED FOR 21 MORE IMPLANTS EFICAS STUDY RESULTS EXPECTED NOVEMBER 2025 Source text: ID:nBw1zGHw4a Further company coverage: ALCAR.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Carmat SA
See all newsBrief: Carmat Receives Takeover Bid
Brief: Carmat SAS Submits Bid For Carmat SA Within Ongoing Receivership Procedure
Brief: Carmat Says Liquidation Review Postponed Until Nov 25
Brief: Carmat: Judiciary Administrator Has Submitted Request To Convert Receivership Into Liquidation To Court
Carmat says imminent liquidation now 'extremely probable'